Vimarsana
Biggest News Aggregation in the World

Page 2 - Nasdaq Hoth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Hoth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Hoth Today - Breaking & Trending Today

Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Up 322.5% in June - Vimarsana News

Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Up 322.5% in June

Hoth Therapeutics, Inc. (NASDAQ:HOTH – Free Report) was the recipient of a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 334,600 shares, a growth of 322.5% from the May 31st total of 79,200 shares. Based on an average daily trading volume, of 1,810,000 shares, […]

Hoth Therapeutics (NASDAQ:HOTH) Trading 3.2% Higher - Vimarsana News

Hoth Therapeutics (NASDAQ:HOTH) Trading 3.2% Higher

Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Rating)’s stock price traded up 3.2% on Wednesday . The company traded as high as $1.60 and last traded at $1.60. 55,712 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 577,703 shares. The stock had previously closed at $1.55. Analyst Upgrades […]

Hoth Therapeutics (NASDAQ:HOTH) Trading Up 0.6% - Vimarsana News

Hoth Therapeutics (NASDAQ:HOTH) Trading Up 0.6%

Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Rating) was up 0.6% during mid-day trading on Tuesday . The company traded as high as $1.78 and last traded at $1.75. Approximately 53,650 shares changed hands during trading, a decline of 92% from the average daily volume of 678,018 shares. The stock had previously closed at $1.74. Analysts […]

Source: wkrb13.com
Hoth Therapeutics' (HOTH) "Speculative Buy" Rating Reaffirmed at Benchmark - Vimarsana News

Hoth Therapeutics' (HOTH) "Speculative Buy" Rating Reaffirmed at Benchmark

Benchmark reaffirmed their speculative buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Get Rating) in a report issued on Monday morning, Benzinga reports. Benchmark currently has a $5.00 price objective on the stock. Separately, EF Hutton Acquisition Co. I dropped their target price on shares of Hoth Therapeutics from $33.00 to $14.00 and set […]

Source: wkrb13.com
Hoth Therapeutics (NASDAQ:HOTH) Given "Speculative Buy" Rating at Benchmark - Vimarsana News

Hoth Therapeutics (NASDAQ:HOTH) Given "Speculative Buy" Rating at Benchmark

Benchmark reaffirmed their speculative buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Get Rating) in a report published on Monday, Benzinga reports. The brokerage currently has a $5.00 price objective on the stock. Separately, EF Hutton Acquisition Co. I reduced their price objective on Hoth Therapeutics from $33.00 to $14.00 and set a buy […]